Reduced levels of amyloid β-peptide antibody in Alzheimer disease

Yansheng Du, R. Dodel, H. Hampel, K. Buerger, S. Lin, B. Eastwood, K. Bales, F. Gao, H. J. Moeller, W. Oertel, Martin Farlow, S. Paul

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1-42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.

Original languageEnglish
Pages (from-to)801-805
Number of pages5
JournalNeurology
Volume57
Issue number5
StatePublished - Sep 11 2001

Fingerprint

Amyloid
Anti-Idiotypic Antibodies
Alzheimer Disease
Peptides
Antibodies
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Serum Amyloid A Protein
Genetically Modified Animals
Amyloid beta-Protein Precursor
Amyloid Plaques
Immunoprecipitation
Transgenic Mice
Immunization
Animal Models
Brain
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Du, Y., Dodel, R., Hampel, H., Buerger, K., Lin, S., Eastwood, B., ... Paul, S. (2001). Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology, 57(5), 801-805.

Reduced levels of amyloid β-peptide antibody in Alzheimer disease. / Du, Yansheng; Dodel, R.; Hampel, H.; Buerger, K.; Lin, S.; Eastwood, B.; Bales, K.; Gao, F.; Moeller, H. J.; Oertel, W.; Farlow, Martin; Paul, S.

In: Neurology, Vol. 57, No. 5, 11.09.2001, p. 801-805.

Research output: Contribution to journalArticle

Du, Y, Dodel, R, Hampel, H, Buerger, K, Lin, S, Eastwood, B, Bales, K, Gao, F, Moeller, HJ, Oertel, W, Farlow, M & Paul, S 2001, 'Reduced levels of amyloid β-peptide antibody in Alzheimer disease', Neurology, vol. 57, no. 5, pp. 801-805.
Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B et al. Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology. 2001 Sep 11;57(5):801-805.
Du, Yansheng ; Dodel, R. ; Hampel, H. ; Buerger, K. ; Lin, S. ; Eastwood, B. ; Bales, K. ; Gao, F. ; Moeller, H. J. ; Oertel, W. ; Farlow, Martin ; Paul, S. / Reduced levels of amyloid β-peptide antibody in Alzheimer disease. In: Neurology. 2001 ; Vol. 57, No. 5. pp. 801-805.
@article{0ddd3b2d20c44b01a9f9170218f11a02,
title = "Reduced levels of amyloid β-peptide antibody in Alzheimer disease",
abstract = "Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1-42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.",
author = "Yansheng Du and R. Dodel and H. Hampel and K. Buerger and S. Lin and B. Eastwood and K. Bales and F. Gao and Moeller, {H. J.} and W. Oertel and Martin Farlow and S. Paul",
year = "2001",
month = "9",
day = "11",
language = "English",
volume = "57",
pages = "801--805",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Reduced levels of amyloid β-peptide antibody in Alzheimer disease

AU - Du, Yansheng

AU - Dodel, R.

AU - Hampel, H.

AU - Buerger, K.

AU - Lin, S.

AU - Eastwood, B.

AU - Bales, K.

AU - Gao, F.

AU - Moeller, H. J.

AU - Oertel, W.

AU - Farlow, Martin

AU - Paul, S.

PY - 2001/9/11

Y1 - 2001/9/11

N2 - Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1-42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.

AB - Objective: To investigate whether it was possible to detect the presence and different levels of naturally occurring anti-β-amyloid (Aβ) antibodies in the CSF of patients with AD and age-matched controls by employing a sensitive ELISA. Background: Immunization with preaggregated amyloid β-peptide (Aβ1-42) and administration of antibodies against Aβ into amyloid precursor protein APPV717F- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Aβ clearance from brain. Methods: A sensitive ELISA was performed to detect levels of naturally occurring anti-Aβ antibodies in the CSF of patients with AD and age-matched controls. Additionally, an immunoprecipitation assay was performed to confirm that naturally occurring anti-Aβ antibodies also exist in the human blood. Result: Naturally occurring antibodies directed against Aβ were found in the CSF and plasma of patients with AD and healthy control subjects. Moreover, CSF anti-Aβ antibody titers are significantly lower in patients with AD compared with healthy control subjects. Conclusion: Naturally occurring antibodies directed against Aβ exist in human CSF and plasma. The CSF anti-Aβ antibody titers may be helpful in better understanding the effects of future immunologic therapies for AD.

UR - http://www.scopus.com/inward/record.url?scp=0035845614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035845614&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 801

EP - 805

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -